APhA Immunization Exam Questions With
Correct Answers
What |is |the |minimum |needle |length |recommended |for |administering |HepB |vaccine |to |an |adult
|patient |weighing |130 |lb? |- |CORRECT |ANSWER✔✔-Fixed |1-inch |needles |are |acceptable |for |
patients |weighing |60 |kg |(132 |lb) |or |less.
HZV, |MMR, |rabies, |typhoid, |varicella, |or |yellow |fever |vaccine |should |not |be |administered |to |a |
patient |with |a |history |of |anaphylaxis |to: |- |CORRECT |ANSWER✔✔-Gelatin
Alan |is |a |47-year-old |man |who |has |no |documentation |of |a |primary |series |of |tetanus-
containing |vaccine. |Which |of |the |following |would |be |an |appropriate |primary |series |for |Alan? |- |
CORRECT |ANSWER✔✔-1) |Tdap
2) |Td |4 |weeks |later
3) |Td |6-12 |months |later
Td |booster |every |10 |years |after |3rd |dose
Candidate |for |PPSV23? |- |CORRECT |ANSWER✔✔-All |adults |65+ |years
Immunocompromised |(alcoholism, |chronic |liver; |heart; |lung |disease, |diabetics, |cochlear |
implants, |CSF |leak) |patients |ages |19-64 |
Children |with |asthma |only |if |theyre |treated |with |high |dose |corticosteriods
Name |the |vaccine-preventable |disease |that |may |be |contracted |by |unimmunized |children |from |
adults |serving |as |reservoirs |for |the |disease, |which |causes |a |paroxysmal |cough |and |potentially |
,can |result |in |pneumonia, |seizures, |encephalopathy, |hypoxia, |and |death. |- |CORRECT |
ANSWER✔✔-Pertussis
Which |of |the |following |vaccines |may |be |administered |to |males |and |females |aged |9 |through |
26 |years |to |reduce |the |likelihood |of |acquiring |genital |warts? |- |CORRECT |ANSWER✔✔-9vHPV
Which |of |the |following |key |questions |is |important |to |ask |a |patient |before |administering |IIV? |- |
CORRECT |ANSWER✔✔-Are |you |sick |today?
*Mild |illness |is |okay, |but |moderate |to |severe |acute |illness |need |to |be |resolved |before |getting |
vaccine.
Live |attenuated |vaccines.. |- |CORRECT |ANSWER✔✔-produced |by |weakening |the |virus |or |
bacteria |to |reduce |the |likelihood |that |it |can |cause |disease
end |to |produce |more |persistent, |longer-lasting |immunity |than |inactivated |vaccines
must |replicate |in |order |for |the |body |to |produce |an |immune |response
could |cause |disease |in |immunocompromised |patients
Circulating |antibodies |may |interfere |with |a |live |attenuated |vaccine's |ability |to |replicate.
Inactivated |vaccines... |- |CORRECT |ANSWER✔✔-are |produced |by |killing |the |virus/bacteria
includes |polysaccharide |vaccines |(conjugated |[protein |altered] |or |unconjugated), |toxoids, |or |
cellular |vaccines
, Which |type |of |vaccine |involves |stimulation |of |B |cells |without |the |assistance |of |T |helper |cells? |-
|CORRECT |ANSWER✔✔-A |pure |polysaccharide
*not |recommended |for |children |<2 |because |of |their |immature |immune |system
Conjugated |vaccines.. |- |CORRECT |ANSWER✔✔-provide |longer |lasting |protection
the |immune |response |that |changes |to |a |T |cell |mediated |response |allows |children |<2 |to |form |
an |immune |response
T/F |
Both |live |attenuated |vaccines |and |recombinant |vaccines |mimic |natural |infection |and |involve |T |
cells |in |the |immune |response. |- |CORRECT |ANSWER✔✔-True
The |incubation |period |for |influenza |can |range |from: |- |CORRECT |ANSWER✔✔-1-4 |days
What |is |the |time |interval |for |which |the |development |of |Guillain-Barré |syndrome |following |
influenza |vaccination |would |result |in |a |precaution |for |future |influenza |vaccines? |- |CORRECT |
ANSWER✔✔-6 |weeks
The |monitoring |system |that |health |care |providers |should |use |to |report |serious |adverse |events |
after |vaccination |is: |- |CORRECT |ANSWER✔✔-VAERS
Which |of |the |following |patients |are |appropriate |candidates |for |the |2-dose |schedule |of |HPV9?
|- |CORRECT |ANSWER✔✔-11 |or |12 |year |olds
*if |series |has |not |been |started |by |age |15, |then |a |3 |dose |series |is |needed |
Correct Answers
What |is |the |minimum |needle |length |recommended |for |administering |HepB |vaccine |to |an |adult
|patient |weighing |130 |lb? |- |CORRECT |ANSWER✔✔-Fixed |1-inch |needles |are |acceptable |for |
patients |weighing |60 |kg |(132 |lb) |or |less.
HZV, |MMR, |rabies, |typhoid, |varicella, |or |yellow |fever |vaccine |should |not |be |administered |to |a |
patient |with |a |history |of |anaphylaxis |to: |- |CORRECT |ANSWER✔✔-Gelatin
Alan |is |a |47-year-old |man |who |has |no |documentation |of |a |primary |series |of |tetanus-
containing |vaccine. |Which |of |the |following |would |be |an |appropriate |primary |series |for |Alan? |- |
CORRECT |ANSWER✔✔-1) |Tdap
2) |Td |4 |weeks |later
3) |Td |6-12 |months |later
Td |booster |every |10 |years |after |3rd |dose
Candidate |for |PPSV23? |- |CORRECT |ANSWER✔✔-All |adults |65+ |years
Immunocompromised |(alcoholism, |chronic |liver; |heart; |lung |disease, |diabetics, |cochlear |
implants, |CSF |leak) |patients |ages |19-64 |
Children |with |asthma |only |if |theyre |treated |with |high |dose |corticosteriods
Name |the |vaccine-preventable |disease |that |may |be |contracted |by |unimmunized |children |from |
adults |serving |as |reservoirs |for |the |disease, |which |causes |a |paroxysmal |cough |and |potentially |
,can |result |in |pneumonia, |seizures, |encephalopathy, |hypoxia, |and |death. |- |CORRECT |
ANSWER✔✔-Pertussis
Which |of |the |following |vaccines |may |be |administered |to |males |and |females |aged |9 |through |
26 |years |to |reduce |the |likelihood |of |acquiring |genital |warts? |- |CORRECT |ANSWER✔✔-9vHPV
Which |of |the |following |key |questions |is |important |to |ask |a |patient |before |administering |IIV? |- |
CORRECT |ANSWER✔✔-Are |you |sick |today?
*Mild |illness |is |okay, |but |moderate |to |severe |acute |illness |need |to |be |resolved |before |getting |
vaccine.
Live |attenuated |vaccines.. |- |CORRECT |ANSWER✔✔-produced |by |weakening |the |virus |or |
bacteria |to |reduce |the |likelihood |that |it |can |cause |disease
end |to |produce |more |persistent, |longer-lasting |immunity |than |inactivated |vaccines
must |replicate |in |order |for |the |body |to |produce |an |immune |response
could |cause |disease |in |immunocompromised |patients
Circulating |antibodies |may |interfere |with |a |live |attenuated |vaccine's |ability |to |replicate.
Inactivated |vaccines... |- |CORRECT |ANSWER✔✔-are |produced |by |killing |the |virus/bacteria
includes |polysaccharide |vaccines |(conjugated |[protein |altered] |or |unconjugated), |toxoids, |or |
cellular |vaccines
, Which |type |of |vaccine |involves |stimulation |of |B |cells |without |the |assistance |of |T |helper |cells? |-
|CORRECT |ANSWER✔✔-A |pure |polysaccharide
*not |recommended |for |children |<2 |because |of |their |immature |immune |system
Conjugated |vaccines.. |- |CORRECT |ANSWER✔✔-provide |longer |lasting |protection
the |immune |response |that |changes |to |a |T |cell |mediated |response |allows |children |<2 |to |form |
an |immune |response
T/F |
Both |live |attenuated |vaccines |and |recombinant |vaccines |mimic |natural |infection |and |involve |T |
cells |in |the |immune |response. |- |CORRECT |ANSWER✔✔-True
The |incubation |period |for |influenza |can |range |from: |- |CORRECT |ANSWER✔✔-1-4 |days
What |is |the |time |interval |for |which |the |development |of |Guillain-Barré |syndrome |following |
influenza |vaccination |would |result |in |a |precaution |for |future |influenza |vaccines? |- |CORRECT |
ANSWER✔✔-6 |weeks
The |monitoring |system |that |health |care |providers |should |use |to |report |serious |adverse |events |
after |vaccination |is: |- |CORRECT |ANSWER✔✔-VAERS
Which |of |the |following |patients |are |appropriate |candidates |for |the |2-dose |schedule |of |HPV9?
|- |CORRECT |ANSWER✔✔-11 |or |12 |year |olds
*if |series |has |not |been |started |by |age |15, |then |a |3 |dose |series |is |needed |
